Syndrome News and Research

RSS

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

Scientists find new tools to help understand neurodevelopmental disorders

Research released today shows that scientists are finding new tools to help understand neurodevelopmental disorders like autism and fragile X syndrome. These studies show in new detail how the brain's connections, chemicals, and genes interact to affect behavior.

15 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

BIOTRONIK AG announced that the six-month results of the ENERGY Registry were presented last week by Prof. Raimund Erbel at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference.

14 Nov 2011

Sleep problems may increase risk of fibromyalgia among women

Researchers from Norway have uncovered an association between sleep problems and increased risk of fibromyalgia in women.

14 Nov 2011

UCLA School of Nursing faculty members to present at AHA 2011

A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.

14 Nov 2011

Inflammatory arthritis or autoimmune disease ruled out as cause for joint pain associated with AIs

Researchers exploring why some women who take a common breast cancer drug develop serious joint pain have eliminated two possible causes: inflammatory arthritis and autoimmune disease.

11 Nov 2011

Health benefits of nut consumption

A recent scientific study has revealed the relationship between nut consumption and a high level of serotonin metabolites (an important neurotransmitter) in patients with metabolic syndrome, who are at high risk of cardiovascular disease.

11 Nov 2011

Dramatic rise in obesity, fatty liver disease increases need for transplants

The dramatic rise in obesity is leading to more fatty liver disease in the United States, increasing the need for more transplants at a time when there already is a severe shortage of donated organs.

11 Nov 2011

Conference highlights advances in evidence-based integrative therapies for cancer

Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio. More than 80 abstracts will be presented at the annual meeting, which will be keynoted by National Institutes of Health Director, Francis Collins, MD, PhD.

11 Nov 2011

Children can have successful surgical repairs for hollow or sunken chest

Hollow or sunken chest, the most common congenital deformity of the chest wall affecting one in 300 to one in 400 children, is rarely life-threatening and virtually all children can have successful surgical repairs.

11 Nov 2011

High-fiber diets may lower risk of heart disease, type-2 diabetes in teens

A diet high in fiber - but not necessarily one low in saturated fat or cholesterol - is tied to a lower risk of heart disease and type-2 diabetes in teenagers, according to new findings from Michigan State University.

11 Nov 2011

NYBC receives FDA approval for HEMACORD HPC-C cell therapy

The U.S. Food and Drug Administration today approved HEMACORD, the first licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy.

10 Nov 2011

Maxygen's MAXY-G34 for Acute Radiation Syndrome not considered for BARDA award

Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

10 Nov 2011

Clinical diagnoses of autism may vary widely across centers

To diagnose autism spectrum disorders, clinicians typically administer a variety of tests or scales and use information from observations and parent interviews to classify individuals into subcategories listed in standard psychiatric diagnostic manuals.

10 Nov 2011